Last reviewed · How we verify

NCT01365416

Personalised Medicine for Morbid Obesity

Status unknown Last updated 13 November 2023
What this trial tests

trial in Diabetes in 2,000 participants. Status unknown.

Timeline
9 December 2011
Primary endpoint
29 December 2025
29 December 2025

Quick facts

Lead sponsorImperial College London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,000
Start date9 December 2011
Primary completion29 December 2025
Estimated completion29 December 2025
Sites1 location across United Kingdom

Conditions studied

Sponsor

Imperial College London

Who can join

Adults 18 to 65, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of morbid obesity (BMI \> 40 kg/m2) is increasing rapidly in the UK, but the investigators lack a coherent strategy for detailed assessment and treatment of the individuals affected, who are at high risk of morbidity and early mortality. The investigators already know that more than 1 in 20 severely-obese individuals have a simple genetic cause of their obesity (usually inherited in an autosomal dominant pattern. Bariatric surgery is the most effective treatment for morbid obesity and certain surgeries can result in the remission of type 2 diabetes. However, some patient fail to achieve the weight loss or experience complications and re-operations. The investigators are unable to predict the outcomes of bariatric surgery particularly in relation to type 2 diabetes remission which is crucial for the assessment of risk to benefit balance before wider future applications of the surgery. The investigators want to investigate the mechanism underlying Type 2 diabetes remission after bariatric surgery by A) examining the effect of Mendelian forms of obesity and diabetes on T2D remission, B) studying changes in expression profiling patterns in insulin-responsive tissues, C) identifying of eQTLs, and of other genetic variations affecting T2D remission and D) studying the role of epigenetic variation in T2D remission.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Tracking physical activity using smart phone apps: assessing the ability of a current app and systematically collecting patient recommendations for future development.
    Murphy J, Uttamlal T, Schmidtke KA, Vlaev I, et al · · 2020 · cited 16× · PMID 32013996 · DOI 10.1186/s12911-020-1025-3
  2. Oligogenic inheritance in severe adult obesity.
    Almansoori S, Alsters SI, Yiorkas AM, Nor Hashim NA, et al · · 2024 · cited 2× · PMID 38297031 · DOI 10.1038/s41366-024-01476-9
  3. Severe obesity as an oligogenic condition: evidence from 1714 adults seeking treatment in the UK National Health Service.
    Almansoori S, Amin HA, Alsters SI, Handley D, et al · · 2025 · PMID 41420254 · DOI 10.1186/s40246-025-00895-7
  4. Rapid and long-lasting remodelling of the blood transcriptome following bariatric surgery
    Roux J, Seyres D, Buxton JL, Handley D, et al · · 2025 · DOI 10.1101/2025.06.20.25329990

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Imperial College London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01365416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing